Abstract
Chemical modulation of histone deacetylase (HDAC) activity by HDAC inhibitors (HDACi) is an increasingly important approach for modifying the etiology of human disease. Loss-of-function diseases arise as a consequence of protein misfolding and degradation, which lead to system failures. The ΔF508 mutation in cystic fibrosis transmembrane conductance regulator (CFTR) results in the absence of the cell surface chloride channel and a loss of airway hydration, leading to the premature lung failure and reduced lifespan responsible for cystic fibrosis. We now show that the HDACi suberoylanilide hydroxamic acid (SAHA) restores surface channel activity in human primary airway epithelia to levels that are 28% of those of wild-type CFTR. Biological silencing of all known class I and II HDACs reveals that HDAC7 plays a central role in restoration of ΔF508 function. We suggest that the tunable capacity of HDACs can be manipulated by chemical biology to counter the onset of cystic fibrosis and other human misfolding disorders.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Analysis of multiple gene co-expression networks to discover interactions favoring CFTR biogenesis and ΔF508-CFTR rescue
BMC Medical Genomics Open Access 30 October 2021
-
SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
Scientific Reports Open Access 17 August 2021
-
Quantitating the epigenetic transformation contributing to cholesterol homeostasis using Gaussian process
Nature Communications Open Access 07 November 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout






References
Riordan, J.R. CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701–726 (2008).
Qu, B.H., Strickland, E.H. & Thomas, P.J. Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding. J. Biol. Chem. 272, 15739–15744 (1997).
Boucher, R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Intern. Med. 261, 5–16 (2007).
Balch, W.E., Morimoto, R.I., Dillin, A. & Kelly, J.W. Adapting proteostasis for disease intervention. Science 319, 916–919 (2008).
Powers, E.T., Morimoto, R.I., Dillin, A., Kelly, J.W. & Balch, W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959–991 (2009).
Hutt, D.M., Powers, E.T. & Balch, W.E. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett. 583, 2639–2646 (2009).
Gregersen, N. Protein misfolding disorders: pathogenesis and intervention. J. Inherit. Metab. Dis. 29, 456–470 (2006).
Marks, P.A. & Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84–90 (2007).
Haberland, M., Montgomery, R.L. & Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32–42 (2009).
Scroggins, B.T. et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25, 151–159 (2007).
Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137–1140 (2006).
Adcock, I.M., Tsaprouni, L., Bhavsar, P. & Ito, K. Epigenetic regulation of airway inflammation. Curr. Opin. Immunol. 19, 694–700 (2007).
Lin, H.S. et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862–872 (2007).
Westerheide, S.D., Anckar, J., Stevens, S.M. Jr., Sistonen, L. & Morimoto, R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323, 1063–1066 (2009).
Fischle, W. et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem. 276, 35826–35835 (2001).
Wang, X. et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127, 803–815 (2006).
Kovacs, J.J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005).
Bebok, Z. et al. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J. Physiol. (Lond.) 569, 601–615 (2005).
Lukacs, G.L. et al. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13, 6076–6086 (1994).
Gentzsch, M. et al. Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol. Biol. Cell 15, 2684–2696 (2004).
Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. USA 104, 17335–17340 (2007).
Marks, P.A. & Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497–1511 (2005).
Blander, G. & Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417–435 (2004).
Milne, J.C. & Denu, J.M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 12, 11–17 (2008).
Caci, E. et al. Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis. Biochem. J. 413, 135–142 (2008).
Ekins, S., Nikolsky, Y., Bugrim, A., Kirillov, E. & Nikolskaya, T. Pathway mapping tools for analysis of high content data. Methods Mol. Biol. 356, 319–350 (2007).
Sun, F. et al. Derlin-1 promotes the efficient degradation of cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants. J. Biol. Chem. 281, 36856–36863 (2006).
Wang, X., Koulov, A.V., Kellner, W.A., Riordan, J.R. & Balch, W.E. Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic 9, 1878–1893 (2008).
Wang, X. et al. COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. J. Cell Biol. 167, 65–74 (2004).
Wiseman, R.L., Powers, E.T., Buxbaum, J.N., Kelly, J.W. & Balch, W.E. An adaptable standard for protein export from the endoplasmic reticulum. Cell 131, 809–821 (2007).
Guggino, W.B. & Stanton, B.A. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat. Rev. Mol. Cell Biol. 7, 426–436 (2006).
Dokmanovic, M. et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 6, 2525–2534 (2007).
Chang, S. et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126, 321–334 (2006).
Kasler, H.G. & Verdin, E. Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol. Cell. Biol. 27, 5184–5200 (2007).
Amaral, M.D. Processing of CFTR: traversing the cellular maze–how much CFTR needs to go through to avoid cystic fibrosis? Pediatr. Pulmonol. 39, 479–491 (2005).
Yoo, J.S. et al. Non-conventional trafficking of the cystic fibrosis transmembrane conductance regulator through the early secretory pathway. J. Biol. Chem. 277, 11401–11409 (2002).
Mai, A. The therapeutic uses of chromatin-modifying agents. Expert Opin. Ther. Targets 11, 835–851 (2007).
Herman, D. et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2, 551–558 (2006).
Mai, A. et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol. Pharmacol. 72, 1111–1123 (2007).
Westphal, C.H., Dipp, M.A. & Guarente, L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem. Sci. 32, 555–560 (2007).
Bates, E.A., Victor, M., Jones, A.K., Shi, Y. & Hart, A.C. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26, 2830–2838 (2006).
Rubenstein, R.C., Egan, M.E. & Zeitlin, P.L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. 100, 2457–2465 (1997).
Singh, O.V. et al. Pharmacoproteomics of 4-phenylbutyrate-treated IB3–1 cystic fibrosis bronchial epithelial cells. J. Proteome Res. 5, 562–571 (2006).
Rubenstein, R.C. & Zeitlin, P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med. 157, 484–490 (1998).
Mroz, R.M., Noparlik, J., Chyczewska, E., Braszko, J.J. & Holownia, A. Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. J. Physiol. Pharmacol. 58 (suppl. 5): 453–460 (2007).
Lei, D.C. et al. Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells. Gene Ther. 3, 427–436 (1996).
Devor, D.C., Bridges, R.J. & Pilewski, J.M. Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am. J. Physiol. Cell Physiol. 279, C461–C479 (2000).
Butterworth, M.B., Edinger, R.S., Johnson, J.P. & Frizzell, R.A. Acute ENaC stimulation by cAMP in a kidney cell line is mediated by exocytic insertion from a recycling channel pool. J. Gen. Physiol. 125, 81–101 (2005).
Myerburg, M.M. et al. Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis. J. Biol. Chem. 281, 27942–27949 (2006).
Myerburg, M.M. et al. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L932–L941 (2008).
Acknowledgements
We thank J.P. Clancy (University of Alabama, Birmingham) for the CFBE41o- expressing ΔF508 and the corrected CFBE41o- (WT-HBE41o-) expressing wild-type CFTR. This work was supported by US National Institutes of Health (NIH) grants HL79442 and GM42336 and aid from the Cystic Fibrosis Consortium to W.E.B.; NIH grant NS055781 to J.M.G.; NIH grants DK68196 and DK72506 and aid from the Cystic Fibrosis Consortium to R.A.F.; NIH grant UR98647 and aid from the Cystic Fibrosis Consortium to E.J.S.; NIH grant AG03197 to J.W.K.; NIH grant DK23567 to J.R.R.; NIH grant AG78594 to G.M.; and NIH grant DK075302 and aid from the Canadian Institutes of Health Research to G.L.L. D.M.H. has received support by fellowships from the Canadian Cystic Fibrosis Foundation and the Canadian Institutes of Health Research; D.H. was supported by a fellowship from the Friedreich's Ataxia Research Alliance. T.O. was supported by a fellowship from the Canadian Cystic Fibrosis Foundation.
Author information
Authors and Affiliations
Contributions
The manuscript was written by D.M.H. and W.E.B. D.M.H. from the W.E.B. laboratory was responsible for all western blot assays, iodide efflux data and analyses in CFBE41o- cells. W.K. assisted D.M.H. from the Balch laboratory in providing technical support for assays. D.H. from the J.M.G. laboratory performed all qRT-PCR analysis of CFTR and HDAC expression. A.P.C.R. from the G.M. laboratory performed the microarray analysis. S.N. from the R.A.F. laboratory performed all short-circuit current and western analyses in primary DF/DF-HBE cells, which were obtained through a collaboration with J.M.P. B.H. from the W.E.B. laboratory performed the ChIP analysis. A.S. from the P.J.T. laboratory performed the thermal melt curve analysis of CFTR-NBD1. Y.M. from the W.R.S. laboratory performed the in vitro translation analysis. M.G. performed the cell surface expression of DF508-CFTRextope in primary HBE cells. T.O. from the G.L.L. laboratory performed the cell surface stability analysis. E.J.S. performed the short-circuit analysis of TSA in CFBE41o- cells. J.R.R. performed the cell surface analysis. J.M. from the W.E.B. laboratory performed all pulse chase analyses. J.W.K. laboratory tested the effect of SAHA on L444P-glucoceribrosidase. W.E.B. directed all aspects of the project. R.A.F., P.J.T., E.J.S., W.R.S., J.R.R., M.G., J.M.G., G.L.L., J.R.Y. and G.M. supervised specific aspects of the project. W.E.B., R.A.F., P.J.T., E.J.S., W.R.S., J.R.R., M.G., J.M.G., G.L.L., J.R.Y. and G.M. provided financial support.
Corresponding author
Ethics declarations
Competing interests
J.W.K. is a founder and W.E.B. is a scientific advisor for Proteostasis Therapeutics Inc. of Cambridge, Massachusetts, USA.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–11, Supplementary Table 1 and Supplementary Methods (PDF 8171 kb)
Supplementary Table 2
Microarray data for CFBE41o- cells following HDAC1 and 7 silencing. (XLS 4843 kb)
Rights and permissions
About this article
Cite this article
Hutt, D., Herman, D., Rodrigues, A. et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 6, 25–33 (2010). https://doi.org/10.1038/nchembio.275
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.275
This article is cited by
-
Lynch syndrome, molecular mechanisms and variant classification
British Journal of Cancer (2023)
-
Analysis of multiple gene co-expression networks to discover interactions favoring CFTR biogenesis and ΔF508-CFTR rescue
BMC Medical Genomics (2021)
-
SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
Scientific Reports (2021)
-
Quantitating the epigenetic transformation contributing to cholesterol homeostasis using Gaussian process
Nature Communications (2019)
-
Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
Scientific Reports (2019)